Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PDE9A | O76083 | 15/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621734 | 0.76 | PDE9A (0.62) | KDM4EPDE9APDE1CHSD11B1 | |
| SCHEMBL5104219 | 0.73 | PARP15 (0.47) | KDM4EPDE9AHSD11B1 | |
| SCHEMBL20870135 | 0.72 | PDE9A (0.55) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL359185 | 0.71 | PDE9A (0.48) | KDM4EPDE9APDE1C | |
| SCHEMBL22206950 | 0.71 | PIM1 (0.44) | KDM4EPDE9APDE1C | |
| SCHEMBL5529450 | 0.71 | PDE9A (0.51) | KDM4EPDE9APDE1C | |
| SCHEMBL4754631 | 0.71 | KDM5A (0.69) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL2870927 | 0.71 | KDM5A (0.47) | KDM4EPDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL4753505 | 0.71 | KDM5A (0.57) | PDE9AKDM5AKDM5CKDM5B | |
| SCHEMBL14177931 | 0.70 | PDE9A (0.47) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1861407-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS | 2006-10-12 | — | — | US | disclosed |
| WO-2006102191-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | MIF, MMP12, MSR1 | KDM4E 1648/4885PDE9A 1744/4885KDM5A 2405/4885 |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4691/4885PDE9A 3677/4885KDM5A 4732/4885 |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | MIF, MMP12, MSR1 | KDM4E 1648/4885PDE9A 1744/4885KDM5A 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.